Technology Enhanced Nurse Navigator Trial (TENN Trial) (TENN)
16 avril 2015 mis à jour par: Mercy Medical Center
Technology Enhanced Nurse Navigator Trial (TENN Trial) Phase III Randomized Controlled Trial
The purpose of the Technology Enhanced Nurse Navigator Trial (TENN) Trial is to find the best way to provide breast cancer patients with information through a computer connected to the internet.
The study will determine if giving information during treatment may help patients cope better with their treatment.
The hypothesis is that participants assigned to receive Technology-Enhanced Nurse-directed Navigation will be more likely to adhere to treatment regimens and have improved symptom management than women who have access to the education portal only.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
Treatment for breast cancer has been proven to decrease death from breast cancer.
The key to the success of treatment is getting the right dose at the right time, but many women do not receive optimum treatment.
Treatment delays, missed appointments, and failure to take medication on a regular basis lead to poorer survival from breast cancer.
In a study among low income women only 60% of women adhered to the treatment, that is, taking their medication at least 80% of the time.
Twenty percent of women, who were supposed to take 5 years of hormone treatment, had stopped their medication in the first year.
Similar problems occur with chemotherapy and radiation therapy.
Many barriers interfere with adherence to treatment, including poor symptom management, missed appointments, and cancelled appointments.
Nurse navigation can help manage and minimize symptoms, assist with appointment reminders, and answer questions to obtain optimum breast cancer treatment.
The goal of the proposed study is to rigorously test the delivery of nurse-navigation through a web-based knowledge and communication portal (Technology Enhanced Nurse-directed Navigation (TENN) for its impact on treatment adherence and symptom management.
The success of this program will be measured by improved treatment adherence, health outcome measures such as fatigue and symptom management, patient-reported quality of life, reduced distress, and patient satisfaction.
Type d'étude
Interventionnel
Inscription (Réel)
101
Phase
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21202
- The Prevention and Research Center at Mercy Medical Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Femelle
La description
Inclusion Criteria:
- Enrolled in the BCCDT program for the adjuvant treatment of breast cancer,currently on medical assistance,or with an income that does not exceed 300% of the Federal Poverty Level, based on family size.
- English-speaking
- Able to give informed consent
- Not enrolled in another case-management program
- Residing within the Verizon 3G Coverage area
Exclusion Criteria:
- Non-English speaking
- Enrolled in a case management program.
- Unable to sign an informed consent
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Interactive navigational support
Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
|
Interactive navigational support is provided by a nurse and social worker navigators
|
|
Comparateur actif: control arm
Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
|
a netbook computer with internet access is provided to participants on the control arm.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment Adherence
Délai: Baseline, 6 months and 12 months
|
Adherence will be determined by review of the claims data.
All claims, including hormone, chemotherapy and radiation therapy, doctor's visits, and hospitalizations, are sent through the BCCDT program.
For chemotherapy and radiation therapy, relative dose intensity (RDI) will be measured.
Adherence to hormone therapy will be measured as the medication possession ratio (MPR).A self-reported measure of adherence will be correlated with these more objective measures (Morisky et al. 1986).
|
Baseline, 6 months and 12 months
|
|
Fatigue
Délai: Baseline, 6 months and 12 months
|
Fatigue will be measured using a visual analogue scale.
The FACT-B will be used to measure quality of life.
The FACT-B is the Functional Assessment of Cancer Therapy-Breast, a reliable and valid measure for assessing subjective health-related quality of life among breast cancer survivors (Brady et al. 1997).
The FACT-B includes both the FACT-General (FACT-G) and the Breast Cancer Subscale (BCS).
The FACT-B has shown high internal consistency with a Cronbach's alpha of 0.90 (Brady et al. 1997).
|
Baseline, 6 months and 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient satisfaction
Délai: Baseline, 6 months and 12 months
|
As recommended by the NCI Navigation Research Program, we will include the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer) designed to measure self-efficacy and positive attitude for cancer patients (Wolf et al. 2005).
|
Baseline, 6 months and 12 months
|
|
Quality of life
Délai: Baseline, 6 months and 12 months
|
As a measure of distress, we will use the Impact of Events scale revised (IES-R), an updated version of the original Impact of Events scale (IES) (Horowitz et al. 1979;Weiss et al. 1997).
The IES-R is a validated measure of responses to a stressful life event and addresses distress and intrusive thoughts consistent with responses to the DSM-IV diagnosis criteria of PTSD.
The IES-R is readily modified to address an event such as diagnosis of cancer or a chemotherapy-related adverse event
|
Baseline, 6 months and 12 months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Kathy Helzlsouer, M.D., M.H.S., The Prevention and Research Center at Mercy Medical Center
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 février 2012
Achèvement primaire (Réel)
1 février 2015
Achèvement de l'étude (Réel)
1 février 2015
Dates d'inscription aux études
Première soumission
8 mai 2012
Première soumission répondant aux critères de contrôle qualité
9 mai 2012
Première publication (Estimation)
10 mai 2012
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
17 avril 2015
Dernière mise à jour soumise répondant aux critères de contrôle qualité
16 avril 2015
Dernière vérification
1 janvier 2015
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- MMC2011-001
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .